Deciduous Therapeutics
Small-molecule senolytic drugs that selectively eliminate senescent cells to treat age-related diseases
- Sector
- Biotech
- Headquarters
- SAN FRANCISCO, CA
- Founded
- 2018
- Latest Form D
- $5.8M, Jul 2019
- Total capital
- $5.8M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $5.8M
- 1 Form D · last Jul 2019
- 88 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 5 pending · first 2024
- Rank in peer group#397 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$5.8M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#397 · top 27%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Anil BhushanDirectorNamed in SEC Form D filings
- Dylan MorrisDirectorNamed in SEC Form D filings
- Robin MansukhaniExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 7- GrantedCompounds For Activating Invariant Natural Killer T-cells And Methods Of Use In Eliminating Inflammatory Senescent CellsUSPTOUS 12,655,171
- PendingInvariant Natural Killer T-cell ActivatorsUSPTOApplication 19107539
- GrantedCompounds For Activating Invariant Natural Killer T-cells And Methods Of Use In Eliminating Inflammatory Senescent CellsUSPTOUS 12,037,357
Show all 7 patent records
- Compounds For Activating Invariant Natural Killer T-cells And Methods Of Use In Eliminating Inflammatory Senescent CellsJun 16, 2026 · US 12,655,171Granted
- Invariant Natural Killer T-cell ActivatorsDec 18, 2025 · Application 19107539Pending
- Compounds For Activating Invariant Natural Killer T-cells And Methods Of Use In Eliminating Inflammatory Senescent CellsJul 16, 2024 · US 12,037,357Granted
- Invariant Natural Killer T-cell ActivatorsApplication PCTUS2023031720Pending
- Invariant Natural Killer T-cell ActivatorsApplication 63402921Pending
- Compounds For Activating Invariant Natural Killer T-cells And Methods Of Use In Eliminating Inflammatory Senescent CellsApplication PCTUS2022018151Pending
- Compounds For Activating Invariant Natural Killer T-cells And Methods Of Use In Eliminating Inflammatory Senescent CellsApplication 63155200Pending
Related companies, and why
- BioIncept, LLCSimilar federal contract value in Biotech · null in contracts
- Diceros Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- BIOPHY, INC.Similar federal contract value in Biotech · null in contracts
- AdimabSimilar federal contract value in Biotech · null in contracts
- AvitideSimilar federal contract value in Biotech · null in contracts
- NEXGENIA, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .